pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Cardamyst
drug · small molecule
save

etripamil

Marketedupdated 6mo ago
by $MIST Milestone Pharmaceuticals Inc.🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 1
  • tagApproval4 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for cardiovascular disease and 3 investigational indications.

indications

investigational
Atrial Fibrillation

all catalysts(0)

nothing on the calendar yet

Trials studying etripamil

  • phase3Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardiacompletedn=500
  • phase3Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302terminatedn=169
  • phase2ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2completedn=69
  • phase3Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).terminatedn=1,097
  • phase3Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303completedn=1,116

Patent cliff

source: FDA Orange Book
first barrier falls
Jun 19, 2028
~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

  • Jul 15, 2042method-of-use (U-4370)US 12257224
  • Apr 13, 2036formulationUS 10117848
  • Jun 19, 2028method-of-use (U-38)US 100105221.6y
  • Jun 19, 2028compositionUS 100105231.6y
  • Jun 19, 2028formulationUS 92279181.6y
  • Jun 19, 2028method-of-use (U-4370)US 94631791.6y

FDA exclusivities (1)

  • Dec 12, 2030NCENew Chemical Entity (5y)4.1y

News(1)

  • Milestone cuts 20% of staff as Cardamyst sales hit $1M in Q3
    Milestone Pharmaceuticals is cutting costs and staff following the FDA approval of its heart arrhythmia treatment, with two top executives departing the leadership team. The company said in its thi…
    endpoints · 3d ago
brand
Cardamyst
generic
etripamil
indication
Atrial Fibrillation
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?